2021-11-30

[#DIV28SUPER] postdoctoral position at UAB

Dear Colleagues,

 

Please see the ad below for a postdoctoral position at UAB. Please disseminate widely.

 

Addiction Research Postdoctoral Training – UAB Department of Psychiatry

 

The UAB Center for Addiction and Pain Prevention and Intervention (CAPPI) is seeking applications for a 2 year post-doc position under the supervision of Dr. Karen Cropsey. The postdoctoral fellow will work on research developing interventions to treat tobacco, alcohol and opioids in persons with substance use disorders.  Dr. Cropsey focuses on developing treatments that can implemented at the point of contact in the criminal justice system and HIV clinics with underserved and stigmatized persons with substance use disorders. These studies focus on providing interventions in urban and rural Southern regions of the U.S. as well as a newly funded P01 grant collaboration with investigators in Zambia.

 

The ideal candidate will have a doctoral degree in clinical psychology, epidemiology, experimental psychology, or public health with an emphasis on substance use with a strong background in clinical research. Knowledge and training in statistics and experience/training using a statistical software (e.g., SPSS, SAS, etc.) is required. In addition, strong communication and writing skills are needed for this position. The ideal candidate would be willing to move to Birmingham for the position.

 

Responsibilities include but are not limited to

- Project management

- Supporting development of data collection tools

- Analysis of existing quantitative data

- Leading and supporting manuscript writing

- Leading and supporting grant proposal development and writing

- Mentoring undergraduate and graduate students

 

Basic Qualifications

- PhD

 

Additional Qualifications

- Experience working with criminal justice involved, persons living with HIV and/or substance using populations is highly desirable

 

Ample opportunities for professional development, mentorship, academic and research leadership, publication, and grant development will be provided through the interdisciplinary training environment in the UAB School of Medicine and Department of Psychiatry.  Pilot funding to establish an independent line of research will be provided through CAPPI. Through her NIH-funded research (NIDA and NIAAA), Dr. Cropsey collaborates closely with community partners, UAB and other U.S. faculty, and Sub-Saharan African partners with expertise in addiction, epidemiology, biostatistics, and behavioral psychology. This opportunity involves being part of a team of interdisciplinary faculty, trainees and staff collaborating through the UAB Center for Addiction and Pain Prevention Intervention (CAPPI; https://www.uab.edu/cappi/). Additional professional development opportunities are available through the UAB Center for Clinical and Translational Sciences and Center for AIDS Research.

https://www.uab.edu/ccts/

https://www.uab.edu/medicine/cfar/

 

About our Postdoc Office:

UAB is committed to the development and success of outstanding postdoctoral scientists. Here at UAB, nearly 300 postdoctoral fellows are training currently in a variety of disciplines. Competitive postdoc awards are available including internships, grant incentives, funds to enhance education and collaboration outside UAB, and teaching opportunities at local universities. There is also a Postdoc Research Day with monetary awards. The Office of Postdoctoral Education strongly encourages UAB research mentors to follow the National Research Service Award stipend level guidelines, and postdoctoral scholars qualify for health, life, and other insurances. They also have the right to participate in the university’s 403(b) program and enjoy vacation, sick leave, maternity/paternity leave, and other benefits.

 

About the University:

The University of Alabama at Birmingham (UAB) is located in Birmingham, Alabama, a region disproportionately impacted by HIV/AIDS. UAB is a publicly funded institution encompassing 11 schools and spanning more than 100 city blocks in downtown Birmingham. Founded in 1969, UAB is an urban university with a major medical center, which has an annual economic impact exceeding $7 billion. Forbes lists UAB among the top 20% of all US undergraduate institutions. UAB has grown rapidly from its beginnings only 50 years ago.  In FY2020, UAB received over $600 million in grants and contracts and is ranked 22nd in the nation and 9th among public institutions for National Institutes of Health (NIH) funding. UAB is currently listed by the Carnegie Foundation in both the highest research tier and in the "community engagement" classification, an indication of how quickly UAB translates research discoveries to benefit the community. In addition, UAB was named America’s Number 1 Best Large Employer 2021 by Forbes https://www.uab.edu/news/campus/item/11852-uab-named-america-s-no-1-best-large-employer-2021-by-forbes and Number 4 Best Employer for Diversity https://www.forbes.com/best-employers-diversity/#7c6c09159b9e. UAB recently received $100 million gift, the largest gift in history for a medical school, which aims to transform and accelerate research at UAB https://www.uab.edu/news/campus/item/12307-100-million-in-gifts-to-transform-uab-school-of-medicine.

UAB is an Equal Opportunity/Affirmative Action Employer committed to fostering a diverse, equitable and family-friendly environment in which all faculty and staff can excel and achieve work/life balance irrespective of, race, national origin, age, genetic or family medical history, gender, faith, gender identity, and expression as well as sexual orientation. UAB also encourages applications from individuals with disabilities and veterans.

For more information on Equal Opportunity and Affirmative Action at UAB, visit the UAB Office of Diversity, Equity and Inclusion or call (205) 934-8762. Or contact the office at 701 20th Street South, AB 336, Birmingham, AL 35294-0103.

Funding. Funding for this position is available for at least 2 years. Salaries for postdocs follow the NIH guidelines https://www.niaid.nih.gov/grants-contracts/salary-cap-stipends plus benefits and four weeks’ vacation. Applicants are eligible to apply for additional research funds and awards through internal pilot grant mechanisms.

 

Deadline: Applications will be reviewed until the position is filled.

 

Applications should be submitted as single PDF document that includes

• One-page statement of academic/research interests

• Academic CV

• Contact information for three academic references

 

Inquiries and Applications should be addressed to:

Karen Cropsey, Psy.D.

Professor, Department of Psychiatry

The University of Alabama at Birmingham

kcropsey@uabmc.edu

 

Thank you,

 

Karen

 

 

Karen Cropsey, Psy.D.

Conatser Turner Endowed Professor of Psychiatry

Vice Chair for Clinical Research

Co-Director, Center for Addiction and Pain Prevention and Intervention

University of Alabama at Birmingham

 

Physical Address:

1670 University Blvd

Volker Hall, Suite L107

Birmingham, AL 35233

 

Email: kcropsey@uab.edu

Phone: 205-975-4204

 

First they came for the Socialists, and I did not speak out—

Because I was not a Socialist.

Then they came for the Trade Unionists, and I did not speak out—

Because I was not a Trade Unionist.

Then they came for the Jews, and I did not speak out—

Because I was not a Jew.

Then they came for me—and there was no one left to speak for me.

 

Martin Niemoller

 

 

[#DIV28SUPER] Tenure Track Job Posting in Psychology Department at California State University, Stanislaus

Please see the following for two tenure track positions:

 

Greetings from the Psychology Department at California State University, Stanislaus,

 

We have two tenure-track faculty positions to fill for the 2022-2023 academic year.

 

One position is at the rank of Assistant or Associate Professor, with a specialty in Clinical Psychology: https://careers.csustan.edu/st/en-us/job/506242/assistantassociate-professor-of-psychology-clinical

 

The other position is at the rank of Assistant Professor with an open area of specialty: https://careers.csustan.edu/st/en-us/job/506240/assistant-professor-of-psychology-stockton-generalist

 

Please distribute these job announcements to potential applicants who are dedicated to diversity and inclusion in education and who are passionate about teaching and mentoring students.

 

Please feel free to reach out to us with any questions about these positions (Clinical: Anita Pedersen, apedersen@csustan.edu; Open Specialty: Kelly Cotter, kcotter@csustan.edu).

 

 

Best,

Brent

 

Brent Kaplan

Assistant Professor

Department of Family and Community Medicine

University of Kentucky

phone: 859-562-2714

email: brentkaplan@uky.edu

bio | github | researchgate

 

The information contained in this e-mail message may be privileged, confidential, and protected from disclosure. If you are not the intended recipient, any further disclosure, use, dissemination, distribution, or copying of this message or any attachment is strictly prohibited. Unauthorized interception or disclosure of this e-mail violates federal criminal law. If you think you have received this e-mail message in error, please delete it and notify the sender immediately.

Re: [#DIV28SUPER] [SUSPICIOUS URL]Re: [#DIV28SUPER] In Memoriam: Dr. David Festinger, Ph.D.

Hello colleagues,

If you would like to donate in the name of Dr. Festinger, you may do so here:

David S. Festinger Memorial Research Fund, www.alumni.pcom.edu/giving

Warm regards,
Kelly
---
Kelly Dunn, Ph.D., M.B.A.
President, Division on Psychopharmacology and Substance Use (Division 28)
American Psychological Association

Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030

From: Celia Fisher <fisher@fordham.edu>
Sent: Monday, November 29, 2021 4:20 PM
To: Kelly Dunn <kdunn9@jhmi.edu>
Cc: DIV28SUPER@lists.apa.org <DIV28SUPER@lists.apa.org>
Subject: [SUSPICIOUS URL]Re: [#DIV28SUPER] In Memoriam: Dr. David Festinger, Ph.D.
 
Dear Kelly,

Thank you for relaying this very sad news. David was a wonderful scientist and terrific person. As you wrote so beautifully, he made distinctive and innovative contributions to the field of substance abuse, ethics, and work with incarcerated populations. His measures and methods continue to guide research in this area. He was a faculty member in our HIV/Drug Abuse Prevention Research Ethics Institute, and our postdoctoral fellows greatly benefited from his wisdom and guidance. They will be saddened by this news. Without burdening you, please let us know if there are steps underway to honor David and whether the family has identified charities or organizations to donate to in his memory.
Celia Fisher

On Mon, Nov 29, 2021 at 4:11 PM Kelly Dunn <00000db27df3fd69-dmarc-request@lists.apa.org> wrote:
Dear colleagues 
 
It is with profound sadness that I share with you that our colleague, Dr. David Festinger, passed away suddenly earlier this month. Dr. Festinger earned his PhD in Clinical Psychology with honors from Hahnemann University in 1998 and at the time of his passing was a Professor of Psychology and the Director of Substance Abuse Research and Education at the Philadelphia College of Osteopathic Medicine, a Senior Research Scientist at the Public Health Management Corporation, and an adjunct Professor in the Department of Psychiatry at the University of Pennsylvania, Perelman School of Medicine. His work largely focused on justice-involved persons, though in recent years he had expanded to also focus on increasing patient access to medications for opioid use disorder. He also conducted a series of research on the ethics of consent in drug use research, which laid a uniquely important foundation for the work we do today. Throughout his career he accumulated several important achievements. His research was continually funded by NIH since 1998, he was the recipient of numerous prestigious awards, and he was a valued scientific citizen who served on numerous editorial boards, grant review committees, IRBs, and more. He was also very prolific, publishing numerous peer-reviewed articles, book chapters, and research bulletins, including serving as a co-editor of the book "Essentials of Research Design and Methodology". 
 
Dr. Festinger was also heavily involved with the APA organization throughout his career. He was an APA Fellow and a member of Division 28 and Division 50 (Addiction). Dr. Festinger served as the Division 28 Awards Chair from 2006-2010 and was elected as President of the Division in 2017. I served as his Program Chair during that year and found him to be a wonderful and caring leader, who was enthusiastic about disseminating science and finding creative and novel methods for improving the life of persons struggling with substance use disorder. I also admired his focus on justice-involved persons for several reasons, most notably the extreme logistical challenge of working in those settings and the direct impact that his interventions had on the individual as well as their family and friends. He worked to not only mitigate the consequences of justice involvement but to also holistically treat the patient by linking them to substance use and medical treatments. To intervene with someone at the point of incarceration and help them work to establish a positive path forward is a tremendously meaningful strategy, it creates a transformative moment that can quite literally change someone's life. In addition to creating opportunities to make real differences in the lives of our patients, his thoughtful and systematic approach to science within the context of drug court settings very likely contributed to a broader acceptance of concepts such as diversion programs and the medical treatment of SUDs within justice systems, a legacy that will continue to yield benefits for our field and our patients.  You can see him describe his research briefly here: https://www.youtube.com/watch?v=ZalHbcAJX0U 
 
It is difficult to adequately convey our gratitude for the impact that Dr. Festinger had on our science, on those of us lucky enough to have interacted with him as a scientific and professional colleague, and on the large numbers of persons who were directly helped by his research. We are thankful to have known him and send condolences to his family, friends, and colleagues.

Warm regards,
Kelly Dunn

---
Kelly Dunn, Ph.D., M.B.A.
President, Division on Psychopharmacology and Substance Use (Division 28)
American Psychological Association

Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28



--
Celia B. Fisher, PhD.
Marie Ward Doty University Chair in Ethics
Professor of Psychology, 
Fordham University, Dealy hall
441 East Fordham Road
Bronx, NY 10458
e. Fisher@fordham.edu  t. (718)817-3793  f. (718)817-0731
Administrative Assistant Lori Merone, lmerone@fordham.edu (718) 817-0926
HIV/Drug Abuse Program Administrator Rimah Jaber, ethicinst@fordham.edu (718) 817-0927
Follow the Ethics Center on Twitter and Facebook: @FordhamEthics and on our blog ethicsandsociety.org
Preferred pronouns: she, her, hers

   

2021-11-29

Re: [#DIV28SUPER] [EXTERNAL] Re: [#DIV28SUPER] In Memoriam: Dr. David Festinger, Ph.D.

David's family have indicated that contributions may be made to the Dr. David S. Festinger Memorial Research Fund, www.alumni.pcom. edu/giving. You need to check the "Other" box from the drop down menu and then type in the fund name.

I believe an obituary will eventually be published in the American Psychologist. So far I am not aware of any other events that have been planned to honor him, but I will keep everyone informed as things develop.  

Thanks to everyone who has inquired.  David was a great colleague and a wonderful friend to all those who were fortunate enough to work closely with him.  He will be sorely missed.

Kim Kirby 


Sent from my iPhone

On Nov 29, 2021, at 4:30 PM, Celia Fisher <fisher@fordham.edu> wrote:


Dear Kelly,

Thank you for relaying this very sad news. David was a wonderful scientist and terrific person. As you wrote so beautifully, he made distinctive and innovative contributions to the field of substance abuse, ethics, and work with incarcerated populations. His measures and methods continue to guide research in this area. He was a faculty member in our HIV/Drug Abuse Prevention Research Ethics Institute, and our postdoctoral fellows greatly benefited from his wisdom and guidance. They will be saddened by this news. Without burdening you, please let us know if there are steps underway to honor David and whether the family has identified charities or organizations to donate to in his memory.
Celia Fisher

On Mon, Nov 29, 2021 at 4:11 PM Kelly Dunn <00000db27df3fd69-dmarc-request@lists.apa.org> wrote:
Dear colleagues 
 
It is with profound sadness that I share with you that our colleague, Dr. David Festinger, passed away suddenly earlier this month. Dr. Festinger earned his PhD in Clinical Psychology with honors from Hahnemann University in 1998 and at the time of his passing was a Professor of Psychology and the Director of Substance Abuse Research and Education at the Philadelphia College of Osteopathic Medicine, a Senior Research Scientist at the Public Health Management Corporation, and an adjunct Professor in the Department of Psychiatry at the University of Pennsylvania, Perelman School of Medicine. His work largely focused on justice-involved persons, though in recent years he had expanded to also focus on increasing patient access to medications for opioid use disorder. He also conducted a series of research on the ethics of consent in drug use research, which laid a uniquely important foundation for the work we do today. Throughout his career he accumulated several important achievements. His research was continually funded by NIH since 1998, he was the recipient of numerous prestigious awards, and he was a valued scientific citizen who served on numerous editorial boards, grant review committees, IRBs, and more. He was also very prolific, publishing numerous peer-reviewed articles, book chapters, and research bulletins, including serving as a co-editor of the book "Essentials of Research Design and Methodology". 
 
Dr. Festinger was also heavily involved with the APA organization throughout his career. He was an APA Fellow and a member of Division 28 and Division 50 (Addiction). Dr. Festinger served as the Division 28 Awards Chair from 2006-2010 and was elected as President of the Division in 2017. I served as his Program Chair during that year and found him to be a wonderful and caring leader, who was enthusiastic about disseminating science and finding creative and novel methods for improving the life of persons struggling with substance use disorder. I also admired his focus on justice-involved persons for several reasons, most notably the extreme logistical challenge of working in those settings and the direct impact that his interventions had on the individual as well as their family and friends. He worked to not only mitigate the consequences of justice involvement but to also holistically treat the patient by linking them to substance use and medical treatments. To intervene with someone at the point of incarceration and help them work to establish a positive path forward is a tremendously meaningful strategy, it creates a transformative moment that can quite literally change someone's life. In addition to creating opportunities to make real differences in the lives of our patients, his thoughtful and systematic approach to science within the context of drug court settings very likely contributed to a broader acceptance of concepts such as diversion programs and the medical treatment of SUDs within justice systems, a legacy that will continue to yield benefits for our field and our patients.  You can see him describe his research briefly here: https://www.youtube.com/watch?v=ZalHbcAJX0U 
 
It is difficult to adequately convey our gratitude for the impact that Dr. Festinger had on our science, on those of us lucky enough to have interacted with him as a scientific and professional colleague, and on the large numbers of persons who were directly helped by his research. We are thankful to have known him and send condolences to his family, friends, and colleagues.

Warm regards,
Kelly Dunn

---
Kelly Dunn, Ph.D., M.B.A.
President, Division on Psychopharmacology and Substance Use (Division 28)
American Psychological Association

Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28



--
Celia B. Fisher, PhD.
Marie Ward Doty University Chair in Ethics
Professor of Psychology, 
Fordham University, Dealy hall
441 East Fordham Road
Bronx, NY 10458
e. Fisher@fordham.edu  t. (718)817-3793  f. (718)817-0731
Administrative Assistant Lori Merone, lmerone@fordham.edu (718) 817-0926
HIV/Drug Abuse Program Administrator Rimah Jaber, ethicinst@fordham.edu (718) 817-0927
Follow the Ethics Center on Twitter and Facebook: @FordhamEthics and on our blog ethicsandsociety.org
Preferred pronouns: she, her, hers

   

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

Re: [#DIV28SUPER] In Memoriam: Dr. David Festinger, Ph.D.

Dear Kelly,

Thank you for relaying this very sad news. David was a wonderful scientist and terrific person. As you wrote so beautifully, he made distinctive and innovative contributions to the field of substance abuse, ethics, and work with incarcerated populations. His measures and methods continue to guide research in this area. He was a faculty member in our HIV/Drug Abuse Prevention Research Ethics Institute, and our postdoctoral fellows greatly benefited from his wisdom and guidance. They will be saddened by this news. Without burdening you, please let us know if there are steps underway to honor David and whether the family has identified charities or organizations to donate to in his memory.
Celia Fisher

On Mon, Nov 29, 2021 at 4:11 PM Kelly Dunn <00000db27df3fd69-dmarc-request@lists.apa.org> wrote:
Dear colleagues 
 
It is with profound sadness that I share with you that our colleague, Dr. David Festinger, passed away suddenly earlier this month. Dr. Festinger earned his PhD in Clinical Psychology with honors from Hahnemann University in 1998 and at the time of his passing was a Professor of Psychology and the Director of Substance Abuse Research and Education at the Philadelphia College of Osteopathic Medicine, a Senior Research Scientist at the Public Health Management Corporation, and an adjunct Professor in the Department of Psychiatry at the University of Pennsylvania, Perelman School of Medicine. His work largely focused on justice-involved persons, though in recent years he had expanded to also focus on increasing patient access to medications for opioid use disorder. He also conducted a series of research on the ethics of consent in drug use research, which laid a uniquely important foundation for the work we do today. Throughout his career he accumulated several important achievements. His research was continually funded by NIH since 1998, he was the recipient of numerous prestigious awards, and he was a valued scientific citizen who served on numerous editorial boards, grant review committees, IRBs, and more. He was also very prolific, publishing numerous peer-reviewed articles, book chapters, and research bulletins, including serving as a co-editor of the book "Essentials of Research Design and Methodology". 
 
Dr. Festinger was also heavily involved with the APA organization throughout his career. He was an APA Fellow and a member of Division 28 and Division 50 (Addiction). Dr. Festinger served as the Division 28 Awards Chair from 2006-2010 and was elected as President of the Division in 2017. I served as his Program Chair during that year and found him to be a wonderful and caring leader, who was enthusiastic about disseminating science and finding creative and novel methods for improving the life of persons struggling with substance use disorder. I also admired his focus on justice-involved persons for several reasons, most notably the extreme logistical challenge of working in those settings and the direct impact that his interventions had on the individual as well as their family and friends. He worked to not only mitigate the consequences of justice involvement but to also holistically treat the patient by linking them to substance use and medical treatments. To intervene with someone at the point of incarceration and help them work to establish a positive path forward is a tremendously meaningful strategy, it creates a transformative moment that can quite literally change someone's life. In addition to creating opportunities to make real differences in the lives of our patients, his thoughtful and systematic approach to science within the context of drug court settings very likely contributed to a broader acceptance of concepts such as diversion programs and the medical treatment of SUDs within justice systems, a legacy that will continue to yield benefits for our field and our patients.  You can see him describe his research briefly here: https://www.youtube.com/watch?v=ZalHbcAJX0U 
 
It is difficult to adequately convey our gratitude for the impact that Dr. Festinger had on our science, on those of us lucky enough to have interacted with him as a scientific and professional colleague, and on the large numbers of persons who were directly helped by his research. We are thankful to have known him and send condolences to his family, friends, and colleagues.

Warm regards,
Kelly Dunn

---
Kelly Dunn, Ph.D., M.B.A.
President, Division on Psychopharmacology and Substance Use (Division 28)
American Psychological Association

Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28



--
Celia B. Fisher, PhD.
Marie Ward Doty University Chair in Ethics
Professor of Psychology, 
Fordham University, Dealy hall
441 East Fordham Road
Bronx, NY 10458
e. Fisher@fordham.edu  t. (718)817-3793  f. (718)817-0731
Administrative Assistant Lori Merone, lmerone@fordham.edu (718) 817-0926
HIV/Drug Abuse Program Administrator Rimah Jaber, ethicinst@fordham.edu (718) 817-0927
Follow the Ethics Center on Twitter and Facebook: @FordhamEthics and on our blog ethicsandsociety.org
Preferred pronouns: she, her, hers

   

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] In Memoriam: Dr. David Festinger, Ph.D.

Dear colleagues 
 
It is with profound sadness that I share with you that our colleague, Dr. David Festinger, passed away suddenly earlier this month. Dr. Festinger earned his PhD in Clinical Psychology with honors from Hahnemann University in 1998 and at the time of his passing was a Professor of Psychology and the Director of Substance Abuse Research and Education at the Philadelphia College of Osteopathic Medicine, a Senior Research Scientist at the Public Health Management Corporation, and an adjunct Professor in the Department of Psychiatry at the University of Pennsylvania, Perelman School of Medicine. His work largely focused on justice-involved persons, though in recent years he had expanded to also focus on increasing patient access to medications for opioid use disorder. He also conducted a series of research on the ethics of consent in drug use research, which laid a uniquely important foundation for the work we do today. Throughout his career he accumulated several important achievements. His research was continually funded by NIH since 1998, he was the recipient of numerous prestigious awards, and he was a valued scientific citizen who served on numerous editorial boards, grant review committees, IRBs, and more. He was also very prolific, publishing numerous peer-reviewed articles, book chapters, and research bulletins, including serving as a co-editor of the book "Essentials of Research Design and Methodology". 
 
Dr. Festinger was also heavily involved with the APA organization throughout his career. He was an APA Fellow and a member of Division 28 and Division 50 (Addiction). Dr. Festinger served as the Division 28 Awards Chair from 2006-2010 and was elected as President of the Division in 2017. I served as his Program Chair during that year and found him to be a wonderful and caring leader, who was enthusiastic about disseminating science and finding creative and novel methods for improving the life of persons struggling with substance use disorder. I also admired his focus on justice-involved persons for several reasons, most notably the extreme logistical challenge of working in those settings and the direct impact that his interventions had on the individual as well as their family and friends. He worked to not only mitigate the consequences of justice involvement but to also holistically treat the patient by linking them to substance use and medical treatments. To intervene with someone at the point of incarceration and help them work to establish a positive path forward is a tremendously meaningful strategy, it creates a transformative moment that can quite literally change someone's life. In addition to creating opportunities to make real differences in the lives of our patients, his thoughtful and systematic approach to science within the context of drug court settings very likely contributed to a broader acceptance of concepts such as diversion programs and the medical treatment of SUDs within justice systems, a legacy that will continue to yield benefits for our field and our patients.  You can see him describe his research briefly here: https://www.youtube.com/watch?v=ZalHbcAJX0U 
 
It is difficult to adequately convey our gratitude for the impact that Dr. Festinger had on our science, on those of us lucky enough to have interacted with him as a scientific and professional colleague, and on the large numbers of persons who were directly helped by his research. We are thankful to have known him and send condolences to his family, friends, and colleagues.

Warm regards,
Kelly Dunn

---
Kelly Dunn, Ph.D., M.B.A.
President, Division on Psychopharmacology and Substance Use (Division 28)
American Psychological Association

Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030

[#DIV28SUPER] University of Florida Center for Behavioral Economic Health Research Postdoctoral Associate and Senior Staff positions

Postdoctoral Research Associate (87187).  The University of Florida Center for Behavioral Economic Health Research (CBEHR) is accepting applications for a postdoctoral research associate to begin in 2022 (start date negotiable). Guided by the trans-discipline of behavioral economics, the CBEHR supports research, applications, and educational initiatives aimed at understanding and promoting beneficial health behavior change. Center-affiliated faculty are engaged in collaborative research projects on substance misuse; HIV, STI, and sexual risk behaviors; physical inactivity; and unhealthy eating behaviors that offer exciting educational opportunities. The postdoctoral research associate will work closely with CBEHR Director Jalie Tucker and other Center faculty members with research programs variously funded by CDC, DOD, NCI, NHLBI, NIA, NIAAA, NIDA, NIMHD, and SAMSHA (CBEHR Faculty). Center investigators utilize a range of laboratory and field research methods including digital applications. The postdoctoral associate will gain skills and expertise to be successful as an independent investigator through participation in existing and planned research projects, manuscript preparation, grant development, seminars and related educational experiences, supervision of Center research assistants and staff, and other Center and professional service activities. This is a time-limited 12-month, non-tenure track position with an initial 2-year appointment, conditional on satisfactory performance. Compensation competitive with NIH postdoctoral fellowship stipend levels. Qualifications: Doctoral degree (or earning the degree by the start date) in psychology, public health, or a related social or behavioral science and demonstrated interest in a research career and a record of research productivity. Interested candidates should submit their CV and a cover letter describing their research experience and interests to Dr. Jalie Tucker (jaliet@ufl.edu). Position URL apply.interfolio.com/99002

 

Research Coordinator Level III (518944).  Independently coordinates community-based human research protocols and related activities in the Department of Health Education and Behavior and Center for Behavioral Economic Health Research under minimal supervision. Serves as the lead staff position for the overall implementation and day-to-day conduct of community-based human research protocols investigating risky drinking and related health behaviors including participant recruitment and retention, data collection, IRB and budget management, and coordination of the work of other research staff and students. Minimum requirements: Bachelor's degree in an appropriate area and 3 years relevant experience; or an equivalent combination of education and experience. Preferred qualifications: Education or experience in community health, human substance use, and/or digital health research applications. Experience with funding applications, IRB protocols, and research-related coordination/administration in collaborative work environments.  Position URL https://explore.jobs.ufl.edu/en-us/job/518944/research-coordinator-iii

 

Thank you very much for bringing this to the attention of potential qualified applicants.

 

Jalie Tucker

CBEHR Director

 

Jalie A. Tucker, Ph.D., M.P.H.

Professor, Department of Health Education and Behavior

College of Health and Human Performance

FLG Room 5, Stadium Road, P.O. Box 118210

University of Florida

Gainesville, FL 32611

Phone:  352.392.0583

FAX:    352.392.1909

email:    jaliet@ufl.edu

 

 

2021-11-22

[#DIV28SUPER] NIDA Neuroscience Update, Nov 22, 2021

Table of Contents

 

I.                     Data Release 4.0 from the Adolescent Brain Cognitive Development StudySM is available now on the NIMH Data Archive

II.                   NIDA AIDS Research Program (ARP) Has been Renamed to NIDA HIV Research Program (HRP)

III.                 Program Officer Position Openings in the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH

IV.                 Job Opening for Program Officer in Program Officer in the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH to Develop and Manage HIV and Substance Misuse Portfolio.

V.                   Job Opening (Health Scientist Administrator, Regulatory Affairs)

------

 

I.                   Data Release 4.0 from the Adolescent Brain Cognitive Development StudySM is available now on the NIMH Data Archive

 

The fourth annual curated ABCD Data Release 4.0 is available now on the NIMH Data Archive. In addition to baseline data on the full participant cohort (nearly 12,000 participants), Data Release 4.0 contains early longitudinal data, including 2-year follow-up neuroimaging data (second imaging timepoint), as well as follow-up phenotypic data for the 6-month, 1-year and 18-month visits on the full cohort. Interim data are also available for the 30-month, 3-year and 42-month visits. Smokescreen genotyping array data with TOPMed imputations are available as well. These include common variations, as well as variations associated with addiction, smoking behavior and nicotine metabolism. Also available are ABCD derived scores from linked external school performance and environmental data, including the Stanford Education Data Archive, EPA Smart Location Database, American Community Survey Area Deprivation Index, FBI’s Uniform Crime Report, lead exposure risk and air pollution indices,  among others. Authorized users can obtain more information and access the updated data from https://nda.nih.gov/abcd. Full details are in the Release Notes for Data Release 4.0. Please contact Elizabeth A. Hoffman, Ph.D  at  elizabeth.hoffman@nih.gov for more information.

-------------

 

II.                 NIDA AIDS Research Program (ARP) Has been Renamed to NIDA HIV Research Program (HRP)

We are pleased to announce that NIDA is renaming the AIDS Research Program (ARP) to the NIDA HIV Research Program (HRP) to better characterize our scientific investment at the intersection of HIV and substance use disorders. The name change aligns our HIV related science with less stigmatizing language, and reflects more contemporary HIV research and management approaches and priorities.  When the ARP program began in 2004, science had only just begun developing improved antiretroviral medications that have transformed HIV from a fatal disease into a manageable and livable condition. NIDA’s HIV research portfolio continues to be the second largest at NIH (after the National Institute of Allergy and Infectious Diseases), and is committed to reducing the stigma that reduces access to care, and can harm mental health. While the name has changed, the mission continues. We will continue to support a wide range of studies, from the basic science of HIV pathogenesis and the immune response in the presence of addictive substances to research on new pre-exposure prophylaxis (PrEP) products among people who use drugs. You can read more about this name change in this blog  from NIDA Director Nora D. Volkow.

 

III.              Program Officer Position Openings in Chemistry Pharmacology Physiology (CPP) Branch the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH

 

Program Officer Opening in Chemistry:

NIDA’s Division of Neuroscience and Behavior (DNB) is recruiting for a Program Officer position within the Chemistry Pharmacology Physiology (CPP) Branch. The Program Officer is expected to develop and oversee a grant portfolio in the rapidly growing field of chemistry and pharmacology of drugs of abuse. The Branch supports all research related to the chemistry and pharmacology of drugs of abuse including the structural dynamics of receptors, computationally-based drug design, intracellular signaling mechanisms, early drug discovery of treatments for addiction, natural product chemistry, and innovative mechanisms of drug delivery. Required areas of expertise includes chemistry, drug design, biophysical and computational approaches, biochemical and neurobiological mechanisms of substance use disorders.

 

Candidates interested in applying for this position should send a cover letter and curriculum vitae to Dr. Sam Ananthan via email at sam.ananthan@nih.gov

 ----------

 

IV.              Job Opening for Program Officer in Program Officer in the Division of Neuroscience and Behavior (DNB) at the National Institute on Drug Abuse, NIH to Develop and Manage HIV and Substance Misuse Portfolio.

 

The Division of Neuroscience and Behavior (DNB) of the National Institute on Drug Abuse (NIDA) is seeking a dynamic motivated individual to serve as a program officer

DNB develops and supports an extramural research portfolio that will advance the understanding of the genetic, chemical, neurobiological and behavioral mechanisms of addictive drugs and their long-term consequences. The Division supports research on the intersection of HIV and substance use disorders. Drug use is not only a vector for the entry of the virus into the circulation, but it can also facilitate brain entry by affecting blood brain barrier permeability.  Additionally, it is associated with risk-taking behavior that increases vulnerability to HIV and other infections. Importantly, substance use can contribute to the course of the disease through independent effects on immune function, by affecting cells that serve as reservoirs of the virus in the brain and through epigenetic mechanisms that regulate latency. Although HIV and addictive drugs can have independent effects on cell biology that contribute to brain diseases, the combination of HIV and drug use can have unique consequences that affect processes such as pain, neurocognitive function and aging. The basic research supported by the DNB provides opportunities to illuminate HIV biology and CNS biology and may provide potential avenues for treating the co-occurrence of HIV and substance use disorder.

The Program Officer will:

  • Assist with the development and coordination of a comprehensive research portfolio at the intersection of HIV and substance use disorder 
  • Provide substantive input into the planning, development, implementation, and evaluation of HIV-related research for the DNB
  • Identify opportunities and problem areas, research gaps and relevant program needs and make recommendations regarding HIV-related research
  • Organize workshops and scientific panels at conferences
  • Serve as DNB liaison with  the NIDA HIV Research Program to coordinate funding plans and research opportunities

Candidate Qualifications:

  • The ideal candidate will possess a PhD in a branch of the biological sciences and ideally will have expertise in neuroscience and HIV.  Interested candidates should send curriculum vitae to Myriam Selmane (selmanem@nida.nih.gov).

-------

 

V.                Job Opening (Health Scientist Administrator, Regulatory Affairs)

The Division of Therapeutics and Medical Consequences (DTMC) of NIDA supports and conducts studies to evaluate the safety and efficacy of new pharmacotherapies, biologics, behavioral therapies, devices, and digital therapeutics for Substance Use Disorders (SUDs). DTMC supports research through peer-reviewed grants and contracts for all stages of medications development including preclinical evaluation of potential therapeutics, clinical trial design and execution, and the preparation of regulatory submissions. The Regulatory Affairs Branch provides expert regulatory guidance and consultation in support of DTMC's medications development efforts. 

 

Regulatory Affairs: The HSA is responsible for providing regulatory expertise and strategies and serves as a liaison between DTMC and other regulatory agencies and organizations  (e.g., Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), Institutional Review Boards (IRBs), and Data Safety Monitoring Boards), research sponsors and collaborators, academic investigators, pharmaceutical companies, and clinical research organizations. The HSA participates in the collection and review of study-specific documents (i.e., research protocols, informed consent documents, etc.) and leads the preparation of regulatory submissions (Investigational New Drug Applications (INDs), Drug Master Files (DMFs), New Drug Applications (NDAs), including amendments, supplements, annual reports, and safety reports. The HSA may serve as a Contracting Officer Representative (COR) with delegated authority to act as a Government representative in monitoring specified aspects of contractor performance in meeting the standards set forth in the contract such as technical, performance, and budgetary requirements. The HSA may also serve as Project Officer/Science Officer to provide scientific and administrative stewardship of extramural grant applications.

If Interested:  Please submit your cover letter, and CV to Robert Walsh, Branch Chief, Regulatory Affairs Branch, rwalsh@nida.nih.gov, 301.827.5244. Vacancy announcement on USAJOBS.gov is currently scheduled to be advertised on January 18, 2022. The successful completion of all requirements for an M.D. or Ph.D. (or equivalent doctoral degree), in an academic field of health-related sciences is required and salary will be commensurate with experience.

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L